We are live on
!
Find out more
DC
Decheng Capital Portfolio holdings
AUM
$661M
1-Year Est. Return
299.97%
This Fund
S&P 500
This Quarter
Est. Return
+33.11%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$358M
AUM Growth
–
Cap. Flow
+$296M
Cap. Flow
% of AUM
82.81%
Top 10 Holdings %
Top 10 Hldgs %
84.63%
Holding
24
New
24
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$98.4M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$30.6M |
| 3 |
Pacific Biosciences
PACB
|
+$24M |
| 4 |
10x Genomics
TXG
|
+$15.6M |
| 5 |
Arcus Biosciences
RCUS
|
+$13.9M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
1
DELISTED
Alpine Immune Sciences Inc
ALPN
| $135M | 37.72% |
+7,083,288
| New | +$98.4M |
|
|
2
Zentalis Pharmaceuticals
ZNTL
$329M
| $31.8M | 8.89% |
+2,099,583
| New | +$30.6M |
|
|
3
Pacific Biosciences
PACB
$432M
| $28.8M | 8.06% |
+2,940,361
| New | +$24M |
|
|
4
10x Genomics
TXG
$5.97B
| $20.1M | 5.62% |
+359,554
| New | +$15.6M |
|
|
IMGN
5
DELISTED
Immunogen Inc
IMGN
| $19.6M | 5.47% |
+659,928
| New | +$13.1M |
|
|
6
Arcus Biosciences
RCUS
$3.4B
| $16.6M | 4.64% |
+869,790
| New | +$13.9M |
|
|
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $14.9M | 4.16% |
+47,000
| New | +$9.14M |
|
8
Roivant Sciences
ROIV
$24.3B
| $14.4M | 4.02% |
+1,279,700
| New | +$12.5M |
|
9
Illumina
ILMN
$29.2B
| $11.3M | 3.15% |
+83,123
| New | +$9.59M |
|
10
argenx
ARGX
$54.6B
| $10.4M | 2.92% |
+27,429
| New | +$12.8M |
|
|
SLRN
11
DELISTED
ACELYRIN
SLRN
| $10.2M | 2.86% |
+1,370,951
| New | +$11.7M |
|
12
Krystal Biotech
KRYS
$10.7B
| $8.16M | 2.28% |
+65,772
| New | +$7.29M |
|
13
Phathom Pharmaceuticals
PHAT
$930M
| $7.76M | 2.17% |
+850,000
| New | +$7.32M |
|
14
Lantheus
LNTH
$6.68B
| $5.72M | 1.6% |
+92,196
| New | +$6.25M |
|
|
TERN
15
DELISTED
Terns Pharmaceuticals
TERN
| $4.64M | 1.3% |
+714,285
| New | +$3.78M |
|
16
Aura Biosciences
AURA
$729M
| $4.57M | 1.28% |
+515,555
| New | +$4.37M |
|
17
BeyondSpring
BYSI
$48.9M
| $4.45M | 1.24% |
+4,958,143
| New | +$4.55M |
|
18
Equillium
EQ
$147M
| $3.22M | 0.9% |
+4,447,308
| New | +$2.64M |
|
19
AtriCure
ATRC
$2.01B
| $1.65M | 0.46% |
+46,259
| New | +$1.72M |
|
|
HLTH
20
DELISTED
Cue Health Inc. Common Stock
HLTH
| $1.46M | 0.41% |
+8,980,909
| New | +$2.98M |
|
21
SCYNEXIS
SCYX
$36M
| $1.24M | 0.35% |
+69,444
| New | +$1.02M |
|
|
WHWK
22
Whitehawk Therapeutics
WHWK
$182M
| $1.06M | 0.3% |
+526,329
| New | +$2.21M |
|
23
Pyxis Oncology
PYXS
$184M
| $588K | 0.16% |
+326,810
| New | +$560K |
|
24
GeneDx Holdings
WGS
$1.84B
| $285K | 0.08% |
+103,604
| New | +$241K |
|
Similar funds
FAM
GC
HIG
RCG
FM
ACM
AWA
UCMOK
Decheng Capital's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Decheng Capital, which disclosed 24 positions worth $358M. Its ten largest holdings account for 85% of the portfolio.
Its largest position is Alpine Immune Sciences Inc: 7,083,288 shares worth $135M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Decheng Capital's largest Q4 2023 buy was Alpine Immune Sciences Inc: 7,083,288 shares worth $135M.
- Decheng Capital's ten largest holdings make up 85% of its $358M portfolio in Q4 2023.
- Decheng Capital disclosed 24 positions in Q4 2023, its first 13F filing on record.
Based on Decheng Capital's 13F filing for Q4 2023, filed 12 Feb 2024.